CD274 and small cell lung carcinoma: The IMpower 133 trial, the first phase III study comparing chemoimmunotherapy versus chemotherapy alone in ES-SCLC, established that adding atezolizumab (PD-L1 inhibitor) to carboplatin-etoposide (EC) significantly improved outcomes.